A controlled trial of propoxyphene and naltrexone in patients with Tourette's syndrome

Ann Neurol. 1991 Jul;30(1):19-23. doi: 10.1002/ana.410300105.

Abstract

To investigate the effect of drugs acting on the endogenous opioid system, we studied 10 adults with Tourette's syndrome who received propoxyphene hydrochloride (260 mg/day), naltrexone hydrochloride (50 mg/day), and placebo in a double-blinded, randomized clinical trial. Using a self-report scale (Tourette's Syndrome Symptom List), subjects noted a significant (p less than 0.04) lessening of tics after treatment with naltrexone when compared with placebo. An improvement in performance on the Trail Making B test, a measure of attention and visuomotor sequencing and planning, occurred after receiving naltrexone when compared with placebo (p less than 0.08) or propoxyphene (p less than 0.02). The Trail Making B test best discriminated the treatments (p less than 0.02, analysis of variance). No other treatment effects were observed for several other measures of tic severity, attentional ability, or obsessive-compulsive symptoms. Our findings indicate that pharmacological manipulation of the endogenous opioid system does influence symptoms of Tourette's syndrome.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Attention
  • Dextropropoxyphene / pharmacology
  • Dextropropoxyphene / therapeutic use*
  • Double-Blind Method
  • Dynorphins / metabolism
  • Endorphins / metabolism
  • Female
  • Humans
  • Male
  • Naltrexone / pharmacology
  • Naltrexone / therapeutic use*
  • Receptors, Dopamine / metabolism
  • Receptors, Opioid / drug effects
  • Severity of Illness Index
  • Tourette Syndrome / drug therapy*
  • Trail Making Test

Substances

  • Endorphins
  • Receptors, Dopamine
  • Receptors, Opioid
  • Naltrexone
  • Dynorphins
  • Dextropropoxyphene